Charles River Laboratories International, Inc. (CRL)
After hours:
| Previous Close | 226.20 |
| Open | 222.00 |
| Bid | 221.42 x 1000 |
| Ask | 222.99 x 900 |
| Day's Range | 218.00 - 224.71 |
| 52 Week Range | 181.36 - 379.65 |
| Volume | |
| Avg. Volume | 626,809 |
| Market Cap | 11.329B |
| Beta (5Y Monthly) | 1.28 |
| PE Ratio (TTM) | 25.92 |
| EPS (TTM) | 8.59 |
| Earnings Date | Feb 14, 2023 - Feb 20, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 269.25 |
- Business Wire
Charles River Launches Endosafe Nexus 200, Emphasizes Critical Importance of Smart Automation for Endotoxin Detection
WILMINGTON, Mass., December 01, 2022--Charles River Laboratories International, Inc. (NYSE: CRL) launches the Endosafe® Nexus 200™, expanding its robust endotoxin testing portfolio. The Nexus 200 is the next evolution of Charles River’s data integrity compliant, fully robotic instrument, capable of processing both undiluted or complex, serial dilutions for water, in-process, and final product testing via Endosafe Limulus Amebocyte Lysate (LAL) cartridge technology in a fully enclosed system. Pow
- Business Wire
Charles River Laboratories Opens Contract Vivarium Space in Chicago, Enhancing Access to AAALAC-Accredited, Turnkey Research Program
WILMINGTON, Mass., November 28, 2022--Charles River recently opened its first location in Chicago, expanding contract vivarium space for the biopharmaceutical industry in Illinois.
- Business Wire
Charles River Laboratories to Present at November Investor Conferences
WILMINGTON, Mass., November 14, 2022--Charles River Laboratories To Present At November Investor Conferences
